Administered weekly at 2.4 mg subcutaneously, semaglutide has secured regulatory clearance in the United States, Europe, the United Kingdom, and Canada for weight management in adults grappling with overweight (BMI 27 kg m2 alongside at least one obesity-related comorbidity) or obesity (BMI 30 kg m2), backed by findings from the Semaglutide Treatment Effect in People with Obesity (STEP) clinical trial program
In March 2026, Eli Lilly signed a $2.75 billion deal with Insilico Medicine, granting global rights to develop drugs discovered using Insilicos generative AI platform
These drugs operate like semaglutide, replicating the physiological effects of GLP-1
Gastrointestinal events were the most common adverse events in both groups and generally occurred during dose escalation
Semaglutide belongs to the broad group of peptides used in metabolism research
At Epi Center MedSpa, we are committed to providing you with the highest standard of care and maintaining the integrity of our treatments